Sensor-Integrated Digital Platform Performs Clinical Trials

BioSensics launches its Sensor-Integrated Digital Platform for measurement and remote monitoring of movement-based biomarkers in clinical trials. The platform combines clinical-grade wearable sensors with turnkey data transfer and storage solutions to enable objective and timely collection of sensor and ePRO data from trial participants.


Clinically-validated algorithms enable assessment of a wide range of endpoints from the sensor data including physical activity, falls, gait, balance, frailty, and fatigue, as well as disease-specific motor symptoms such as tremor, chorea, and foot drop. Relevant therapeutic areas include stroke, Alzheimer’s disease, CNS and musculoskeletal disorders, orthopaedics, oncology, and many others.

Sponsored by Digi-Key

TE Connectivity Horticultural Lighting Solutions Available Now from Digi-Key

TE connector, relay and filter solutions can help create a fine maze network of power-cabling to the lights needed for vertical farming. Their solutions are interchangeable, easy-to-install, and will last for years in variable humidity environments.


The platform is driven by the company’s wearable sensors that gather data from participants during activities of daily living, while also alerting the clinical study staff in case of non-compliance in wearing the sensors. The platform includes a customizable ePRO interface via smartphone or tablet and allows for automatic data transfer to a HIPAA compliant cloud server.


In addition to the Sensor-Integrated Digital Platform, BioSensics offers related clinical trial services based on decades of direct experience in clinical research. An expert team of biomechanists, algorithm development scientists, and biomedical engineers provide hands-on support services at every stage of the trial. Services include scientific consulting, custom algorithms and analytics, data management and reporting, patient follow-up, site-training, and technical support.


For more details, peruse the Sensor-Integrated Digital Platform page and/or call BioSensics at 888-589-6213.


Suggested Articles

According to a new study by Fact.MR, the MEMS sensor market will grow at a compound annual growth rate of 9% through 2027, reaching $50 billion.

RaayonNova founder and CEO Aleksandr Shtukater is developing advanced contact lens technology that can potentially replace smartphones and tablets.

Analyst firm Omdia reverses earlier upbeat projection for smartphone growth in China due to virus impact on supplies like displays